Yeongnam University   Report issue

Academic/Hospital Phase 2 Phase 4
Founded: Gyeongsan Korea, Republic of (1967)

Organization Overview

First Clinical Trial
2010
NCT01259531
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Yeongnam University Hospital | Yeongnam Univ. hospital | Yeongnam Univ. Medical | Yuengnam University

Active Ingredients

Drugs in Phase 4 Trials (4)

naftopil (Flivas) (1 trial)

naloxone (narcan) (1 trial)

oxycodone (oxycontin) (1 trial)

silodosin (rapaflo) (1 trial)

Drugs in Phase 2 Trials (1)

da-8031 (1 trial)

Drugs in Other Trials (2)

bupivacaine (Exparel) (1 trial)

triamcinolone (kenalog) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cancer Pain (Phase 4)

Hyperplasia (Phase 4)

Lower Urinary Tract Symptoms (Phase 4)

Premature Birth (Phase 2)

Premature Ejaculation (Phase 2)

Prostatic Hyperplasia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 7